Acorn Capital Advisors
Latest statistics and disclosures from Acorn Capital Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are CGON, URGN, TRVI, CADL, PBYI, and represent 68.63% of Acorn Capital Advisors's stock portfolio.
- Added to shares of these 6 stocks: KPTI (+$12M), JBIO, AURA, ENGN, CGON, JSPR.
- Started 1 new stock position in ENGN.
- Reduced shares in these 6 stocks: TERN (-$92M), Bioatla (-$22M), CRDF, QTTB, X4 Pharmaceuticals, BCAX.
- Sold out of its positions in CRDF, TERN, X4 Pharmaceuticals.
- Acorn Capital Advisors was a net seller of stock by $-98M.
- Acorn Capital Advisors has $367M in assets under management (AUM), dropping by 4.16%.
- Central Index Key (CIK): 0002054410
Tip: Access up to 7 years of quarterly data
Positions held by Acorn Capital Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Acorn Capital Advisors
Acorn Capital Advisors holds 20 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Cg Oncology (CGON) | 21.9 | $80M | 1.1M | 71.05 |
|
|
| Urogen Pharma (URGN) | 16.8 | $62M | 1.7M | 36.80 |
|
|
| Trevi Therapeutics (TRVI) | 10.9 | $40M | 2.1M | 18.65 |
|
|
| Candel Therapeutics (CADL) | 9.8 | $36M | 3.5M | 10.30 |
|
|
| Puma Biotechnology (PBYI) | 9.1 | $34M | 4.1M | 8.11 |
|
|
| Jade Biosceinces Com New (JBIO) | 6.0 | $22M | +25% | 987k | 22.22 |
|
| Bicara Therapeutics (BCAX) | 5.2 | $19M | 643k | 29.69 |
|
|
| Karyopharm Therapeutics Common Stock (KPTI) | 4.0 | $15M | +427% | 1.5M | 9.77 |
|
| Onkure Therapeutics Class A Com (OKUR) | 3.5 | $13M | 2.8M | 4.56 |
|
|
| Helus Pharma Com Stk (HELP) | 2.8 | $10M | 1.5M | 6.61 |
|
|
| Protara Therapeutics Com Stk (TARA) | 1.8 | $6.7M | 1.8M | 3.82 |
|
|
| Aura Biosciences (AURA) | 1.8 | $6.6M | +55% | 929k | 7.10 |
|
| Leonabio Common Stock (LONA) | 1.6 | $5.8M | 635k | 9.19 |
|
|
| Verastem (VSTM) | 1.5 | $5.6M | 1.5M | 3.82 |
|
|
| Aadi Bioscience (WHWK) | 1.4 | $5.2M | 1.1M | 4.58 |
|
|
| Q32 Bio (QTTB) | 0.8 | $2.8M | -31% | 216k | 12.74 |
|
| Engene Therapeutics (ENGN) | 0.6 | $2.2M | NEW | 1.3M | 1.73 |
|
| Jasper Therapeuritc (JSPR) | 0.2 | $604k | 1.4M | 0.42 |
|
|
| Bioatla | 0.1 | $448k | -98% | 108k | 4.14 |
|
| Vyne Therapeutics (VYNE) | 0.0 | $925.965000 | 1.4k | 0.65 |
|
Past Filings by Acorn Capital Advisors
SEC 13F filings are viewable for Acorn Capital Advisors going back to 2024
- Acorn Capital Advisors 2026 Q2 filed Aug. 14, 2026
- Acorn Capital Advisors 2026 Q1 filed May 15, 2026
- Acorn Capital Advisors 2025 Q4 filed Feb. 17, 2026
- Acorn Capital Advisors 2025 Q3 filed Nov. 17, 2025
- Acorn Capital Advisors 2025 Q2 filed Aug. 14, 2025
- Acorn Capital Advisors 2024 Q4 restated filed May 19, 2025
- Acorn Capital Advisors 2025 Q1 restated filed May 19, 2025
- Acorn Capital Advisors 2025 Q1 filed May 15, 2025
- Acorn Capital Advisors 2024 Q4 amended filed May 7, 2025